ClinicalTrials.gg
RecruitingNCT06525597MIZARUpdated Nov 8, 2024

Study of Stapokibart Injection in Patients With Allergic Rhinitis

A Phase 2 interventional study of Stapokibart Injection and Placebo in Allergic Rhinitis, sponsored by Keymed Biosciences Co.Ltd. Recruiting at 1 site in China. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Rhinitis, Allergic with a site in China — 32 open to participants now, 34 under way, 2 of them phase 3. Rhinitis, Allergic · China.

Planned enrollment
24th of 67
120 · median 93
Started
2024
with 21 others
Phase 2
9 of 82
3 open now
Primary completion
2025-10
later than 12 of 33 live
Registered
54th of 82
by date
Lead sponsor
3 of 82
Keymed Biosciences Co.Ltd

Among the 82 studies in Rhinitis, Allergic with a site in China, this one is the 24th largest by planned enrollment of the 67 interventional ones that give a count, is one of 22 that started in 2024, is one of 9 in phase 2, reaches primary completion later than 12 of the 33 other live ones, and was the 54th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

32 of the 82 studies in Rhinitis, Allergic with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Rhinitis, Allergic with a site in China, or all of them as a file.
02

Study summary

This study is a Randomized, Double-blind, Placebo-controlled phase II clinical study evaluating the efficacy and safety of Stapokibart injection in patients with allergic rhinitis.

Read the detailed description

Allergic rhinitis (AR) is a non infectious chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin E (IgE) in atopic individuals exposed to allergens.

03

Conditions studied

  • Allergic Rhinitis

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand the study and voluntarily sign the form.
  • Diagnosed Allergic Rhinitis according to the Criteria stated in the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition).
  • Subjects with asthma must be evaluated by the researcher as having a stable condition.
  • Has a positive skin prick test (SPT) or positive antigen-specific serum immunoglobulin E (IgE).

Exclusion criteria

Exclusion Criteria:

  • Use of anti-interleukin 4 receptor alpha subunit (IL-4Rα) monoclonal antibody, thymic stromal lymphopoietin (TSLP) monoclonal antibody, anti-IgE monoclonal antibody, other monoclonal antibodies, or other biologics within 10 weeks or 5 half-lives (whichever is longer) prior to the screening visit.
  • Use of any product within 4 weeks prior to the screening visit or planning to participate in other clinical studies during this study.
  • (FEV1) ≤ 50% of the predicted value during the screening/run-in period.
  • Have acute sinusitis, nasal infection, or upper respiratory tract infection at screening or within 2 weeks prior to screening.
  • Have received a within 12 weeks prior to randomization or planning to receive one during the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Stapokibart Group

    Stapokibart, subcutaneous, once every two weeks

    Biological: Stapokibart Injection

  • Placebo comparator
    Placebo Group

    Placebo, subcutaneous, once every two weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in daily reflective total nasal symptom scores (rTNSS) over 4 weeks of treatment.

    The total nasal symptom score (TNSS) is the sum of the four symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, where each symptom is scored on a scale of 0 to 3.

    Time frame: Up to week 4

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Oct 2025, 13 months after the start.

Of 31 phase 2 interventional studies under Rhinitis, Allergic, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's planned 13 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Jul 29, 2024
StartActual
Sep 30, 2024
Primary completionEst.
Oct 30, 2025
CompletionEst.
Oct 30, 2025
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06525597
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Sep 30, 2024
Primary completion
Oct 30, 2025 (estimated)
Completion
Oct 30, 2025 (estimated)
Last update
Nov 8, 2024

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
028-88610620
Luo Zhang
principal investigator · Beijing Tong-Ren hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion